Improvement of glycaemic control by nateglinide decreases systolic blood pressure in drug-naive patients with type 2 diabetes

European Journal of Clinical Investigation

Volumn 38, Issue 3, 2008, Pages 174-179

  Gonzalez Clemente J M ^a  

^a HOSPITAL DE SABADELL   (Spain)

Author keywords

Blood pressure; Drug naive; Homeostasis model assessment; Nateglinide; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; NATEGLINIDE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HOMEOSTASIS; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TEST MEAL;

ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PHENYLALANINE; TRIGLYCERIDES;

EID: 38849168916     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01918.x     Document Type: Article

References (30)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 352 : 854 65.
3. McCormack J, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study. BMJ 2000 320 : 1720 3.
4. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004 256 : 1 14.
5. Amador-Licona N, Guizar-Mendoza J, Vargas E, Sanchez-Camargo G, Zamora-Mata L. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Arch Med Res 2000 31 : 571 5.
6. Sundaresan P, Lykos D, Daher A, Morris R, Diamond T, Howes L. Acute effects of oral glibenclamide on blood pressure and forearm vascular resistance in diabetics. Clin Exp Pharmacol Physiol 1997 24 : 333 5.
7. Peuler JD, Miller JA, Bourghli M, Zammam HY, Soltis EE, Sowers JR. Disparate effects of antidiabetic drugs on arterial contraction. Metab Clin Exp 1997 46 : 1199 205.
8. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 290 : 486 94.
9. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 : 1279 89.
10. Nissen S, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 356 : 2457 71.
11. Derosa G, Cicero A, Gaddi A, Ciccarelli L, Piccinni M, Salvadeo S et al. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther 2005 27 : 1383 91.
12. Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract 2005 70 : 20 5.
13. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004 27 : 1487 95.
14. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 165 : 1410 9.
15. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001 37 : 1053 9.
16. Guerci B, Bohme P, Kearney-Schwartz A, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab 2001 27 : 436 47.
17. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004 15 : 1983 92.
18. Gaede P, Parving HH, Pedersen O. PROactive study. Lancet 2006 367 : 23 4 author reply 6-7.
19. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006 91 : 837 42.
20. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002 105 : 2296 302.
21. Gonzalez-Clemente JM, Ortega-Martinez de Victoria E, Gimenez-Palop O, Mauricio D. Acarbose for patients with hypertension and impaired glucose tolerance. JAMA 2003 290 : 3067 author reply -9.
22. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 1995 96 : 354 60.
23. Anan F, Masaki T, Fukunaga N, Teshima Y, Iwao T, Kaneda K et al. Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus. Eur J Clin Invest 2007 37 : 709 14.
24. Shimabukuro M, Higa N, Takasu N, Tagawa T, Ueda S. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in type 2 diabetic patients. Diabet Med 2004 21 : 983 6.
25. Cameron J, Cruickshank J. Glucose, insulin, diabetes and mechanisms of arterial dysfunction. Clin Exp Pharmacol Physiol 2007 34 : 677 82.
26. Lim H, Lip G. Arterial stiffness in diabetes, hypertension. J Hum Hypertens 2004 18 : 467 8.
27. Langouche L, Vanhorebeek I, Vlasselaers D, Vander Perre S, Wouters P, Skogstrand K et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 2005 115 : 2277 86.
28. Westerbacka J, Wilkinson I, Cockcroft J, Utriainen T, Vehkavaara S, Yki-Järvinen H. Diminished wave reflection in the aorta. A novel physiological action of insulin on large blood vessels. Hypertension 1999 33 : 1118 22.
29. Manzella D, Grella R, Abbatecola A, Paolisso G. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care 2005 28 : 366 71.
30. Becker A, van der Does F, van Hinsbergh V, Heine R, Bouter L, Stehouwer C. Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro) insulin. Neth J Med 2003 61 : 129 36.